Ubrogepant
Overview
Ubrogepant is a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist used for the acute treatment of migraine with or without aura in adults. It offers a new mechanism for migraine relief by targeting the CGRP pathway.
API suppliers (5)
Suppliers of Ubrogepant evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 4 of 5 suppliers.
3 of 5 hold a GMP certificate on record in the EU or UK registers
- Micro Labs Usa1 active DMF
- HONOUR LAB LTDIndia1 active DMF GMP on record
- MSN LIFE SCIENCES PRIVATE LIMITEDIndia1 active DMF GMP on record
- APITORIA PHARMA PRIVATE LTDIndia1 active DMF GMP on record
- Allsino Pharmaceutical Co., Ltd.China1 active DMF
Patent & exclusivity (US)
Per the FDA Orange Book (2 approved US products), the latest listed US patent on Ubrogepant expires 22 Dec 2041. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Ubrogepant? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.